Medtronic Enhances Utility of Professional Continuous Glucose Monitor (CGM) by Launching Pattern Snapshot for iPro®2 Profess...
November 30 2015 - 9:00AM
Simplified Report
Uses New Algorithms to Streamline Diabetes Data Interpretation for
the Health Care Professional
DUBLIN - November 30, 2015 -
Medtronic plc (NYSE:MDT), the global leader in medical technology,
today announced the availability of a new CareLink®
iPro report called Pattern Snapshot for iPro2 Professional CGM
system. The new one-page report provides a health care professional
(HCP) with information for quick interpretation of detailed glucose
data over time. The identified patterns are based on advanced
algorithms that automatically identify an individual's top glucose
control issues and their possible causes. The report information
and visuals also serve as a teaching tool to help educate people
with diabetes about their own glucose profile.
The iPro2 system provides physicians with insights
into how their patients' diet, medication, and daily activities
affect glucose levels. Much like a holter monitor for
cardiovascular care, the iPro2 Professional CGM device records a
patient's glucose levels 24 hours a day for up to three days and
provides user-friendly reports to the physician. The physicians
accordingly use these simple reports to make therapy adjustments,
recommendations and educational decisions for their
patients.
"We developed this rule-based, simplified report to enhance
the use of professional CGM as part of the overall diabetes
management regimen," stated Laura Stoltenberg, general manager of
Medtronic's Non-Intensive Diabetes Therapies business unit. "HCPs
will now have a simplified report that will allow for faster
interpretation of the most important diabetes metrics, so they can
quickly uncover their patient's most important issues."
Pattern Snapshot identifies the top three issues
in a patient's glucose profile, providing details of each priority
issue. This includes possible causes for each pattern, as well as
visuals of meal times and daily glucose values, thereby allowing
physicians to uncover more information in less time.
"The retrospective CGM technology of Medtronic's
iPro2 Professional CGM presents the patient and provider with
accurate information that allows personalized treatment
decisions. This comprehensive yet easy-to-interpret
continuous glycemic data will arm the care team with valuable and
previously difficult to obtain data," said Todd M. Zeiger, M.D.,
vice president, UH Primary Care Institute, Cincinnati, OH.
The use of professional CGM is on the rise in the
U.S. Several published studies have shown the benefits of
professional CGM in modifying treatment, capturing more episodes of
low blood sugar, which can be a serious condition if left
untreated, and as an educational tool for improved glycemic
control.i, ii,
iii
To learn more about the iPro2 Professional CGM
system visit:
http://professional.medtronicdiabetes.com/ipro2-professional-cgm
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 85,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
i Hirsch IB, Amiel SA, Blumer IR, et al. [need to
have three authors cited before "et al"] Using multiple measure of
glycemia to support individualized diabetes management:
recommendations for clinicians, patients, and payers. Diabetes Technol Ther. 2012; 14(11):973-983.
ii Munshi MN, Segal AR, Suhl E, et al. Frequent
hypoglycemia among elderly patients with poor glycemic control.
Arch Intern Med. 2011;171(4):362-364.
iii Tanenberg R, et al. Mayo
Clinic Proceedings. 2004;79(12):1521-6
Contacts:
Amanda Sheldon
Public Relations
+1-818-576-4826
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
HUG#1970009
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024